Michael Wang

44.3k total citations · 5 hit papers
554 papers, 16.3k citations indexed

About

Michael Wang is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Michael Wang has authored 554 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 304 papers in Pathology and Forensic Medicine, 261 papers in Oncology and 204 papers in Genetics. Recurrent topics in Michael Wang's work include Lymphoma Diagnosis and Treatment (293 papers), Chronic Lymphocytic Leukemia Research (195 papers) and CAR-T cell therapy research (107 papers). Michael Wang is often cited by papers focused on Lymphoma Diagnosis and Treatment (293 papers), Chronic Lymphocytic Leukemia Research (195 papers) and CAR-T cell therapy research (107 papers). Michael Wang collaborates with scholars based in United States, China and United Kingdom. Michael Wang's co-authors include Joseph L. Goldstein, Michael S. Brown, Rodney E. Infante, Hyock Joo Kwon, Jorge Romaguera, Preetesh Jain, Robert L. Garcea, Suchitra Rao, Larry W. Kwak and Luis Fayad and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael Wang

517 papers receiving 16.0k citations

Hit Papers

Lenalidomide plus Dexamethasone for Relapsed Multiple Mye... 2007 2026 2013 2019 2007 2016 2019 2009 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
    2007 925 citations Donna M. Weber, Christine Chen et al. profile →
  2. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
    2016 596 citations Michael Wang et al. Blood profile →
  3. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
    2019 594 citations Yucai Wang, Shouhao Zhou et al. profile →
  4. Seroepidemiology of Human Polyomaviruses
    2009 570 citations Michael Wang et al. profile →
  5. Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol
    2009 515 citations Michael Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Wang United States 62 8.2k 5.9k 4.8k 4.0k 3.2k 554 16.3k
Steven T. Rosen United States 61 5.7k 0.7× 4.5k 0.8× 6.5k 1.4× 1.5k 0.4× 1.9k 0.6× 423 15.9k
Leo I. Gordon United States 65 6.6k 0.8× 2.3k 0.4× 8.0k 1.7× 1.2k 0.3× 3.0k 0.9× 453 15.0k
Richard Greil Austria 67 10.9k 1.3× 5.3k 0.9× 4.2k 0.9× 2.3k 0.6× 3.0k 1.0× 731 20.1k
Mark D. Minden Canada 69 7.0k 0.9× 12.1k 2.1× 1.5k 0.3× 8.3k 2.1× 2.9k 0.9× 509 23.6k
Dieter Hoelzer Germany 62 4.6k 0.6× 4.6k 0.8× 3.4k 0.7× 7.3k 1.8× 4.6k 1.4× 322 16.5k
Gilles Salles France 84 17.1k 2.1× 5.1k 0.9× 23.0k 4.8× 2.8k 0.7× 10.2k 3.2× 763 34.7k
Ofer Shpilberg Israel 46 3.7k 0.5× 1.9k 0.3× 3.4k 0.7× 3.3k 0.8× 2.1k 0.7× 261 9.2k
Carsten Müller‐Tidow Germany 64 4.3k 0.5× 11.4k 1.9× 787 0.2× 5.3k 1.3× 1.8k 0.6× 492 18.0k
John F. DiPersio United States 70 5.9k 0.7× 6.4k 1.1× 1.3k 0.3× 12.0k 3.0× 3.2k 1.0× 596 20.8k
Marina Konopleva United States 94 7.9k 1.0× 15.8k 2.7× 2.0k 0.4× 15.6k 3.9× 5.9k 1.8× 917 30.5k

Countries citing papers authored by Michael Wang

Since Specialization
Citations

This map shows the geographic impact of Michael Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wang more than expected).

Fields of papers citing papers by Michael Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wang. The network helps show where Michael Wang may publish in the future.

Co-authorship network of co-authors of Michael Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Wang. A scholar is included among the top collaborators of Michael Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Wang. Michael Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Michael, et al.. (2025). BPS2025 - Cell stochastic resonance and memory: New mechanisms underlying complex pacemaker function. Biophysical Journal. 124(3). 597a–597a.
2.
Lee, Heng‐Huan, Ravi Prakash Shukla, Violetta V. Leshchenko, et al.. (2024). Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance. Blood. 144(Supplement 1). 1402–1402. 1 indexed citations
3.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2024). Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.. Journal of Clinical Oncology. 42(16_suppl). 7007–7007. 4 indexed citations
4.
Jain, Preetesh, Krystle Nomie, Nikita Kotlov, et al.. (2023). IMMUNE‐DEPLETED TUMOR MICROENVIRONMENT IS ASSOCIATED WITH POOR OUTCOMES AND BTK INHIBITOR RESISTANCE IN MANTLE CELL LYMPHOMA. Hematological Oncology. 41(S2). 190–190.
5.
6.
Hill, Holly A., Preetesh Jain, Chi Young Ok, et al.. (2023). Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma. Cancer Research Communications. 3(8). 1435–1446. 3 indexed citations
7.
8.
Jain, Preetesh, Guilin Tang, Shaoying Li, & Michael Wang. (2020). “Triple hit” SOX11−, MME+, TP53 mutated high‐grade pleomorphic mantle cell lymphoma. American Journal of Hematology. 96(1). 165–166.
9.
Kulkarni, Amit, Beibei Xu, Haitao Chu, et al.. (2020). Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer Journal. 10(3). 33–33. 26 indexed citations
10.
Rule, Simon, Martin Dreyling, André Goy, et al.. (2019). Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. Blood. 134(Supplement_1). 1538–1538. 16 indexed citations
11.
Jain, Preetesh & Michael Wang. (2019). Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. American Journal of Hematology. 94(6). 710–725. 148 indexed citations
12.
Pham, Lan V., Shengjian Huang, Hui Zhang, et al.. (2018). Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clinical Cancer Research. 24(16). 3967–3980. 63 indexed citations
13.
Kuruvilla, John, Michael R. Savona, Rachid Baz, et al.. (2017). Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 129(24). 3175–3183. 112 indexed citations
14.
Oki, Yasuhiro, Michelle A. Fanale, Jorge Romaguera, et al.. (2015). Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology. 171(4). 463–470. 68 indexed citations
15.
Kuiatse, Isere, Veerabhadran Baladandayuthapani, Heather Lin, et al.. (2015). Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clinical Cancer Research. 21(11). 2538–2545. 16 indexed citations
16.
Zhang, Liang, Lan V. Pham, Kate J. Newberry, et al.. (2013). In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome. Molecular Cancer Therapeutics. 12(11). 2494–2504. 22 indexed citations
17.
Zhang, Liang, Jing Yang, Jianfei Qian, et al.. (2012). Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 120(18). 3783–3792. 88 indexed citations
18.
Ma, Wencai, Michael Wang, Zhiqiang Wang, et al.. (2010). Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiology Biomarkers & Prevention. 19(10). 2445–2452. 35 indexed citations
19.
Wang, Michael, Yasuhiro Oki, Barbara Pro, et al.. (2009). Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. 27(31). 5213–5218. 66 indexed citations
20.
Wang, Michael, Meletios Α. Dimopoulos, Christine Chen, et al.. (2008). Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 112(12). 4445–4451. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven T. Rosen Breakdown of academic impact, for papers by Leo I. Gordon Breakdown of academic impact, for papers by Richard Greil Breakdown of academic impact, for papers by Mark D. Minden Breakdown of academic impact, for papers by Dieter Hoelzer Breakdown of academic impact, for papers by Gilles Salles Breakdown of academic impact, for papers by Ofer Shpilberg Breakdown of academic impact, for papers by Carsten Müller‐Tidow Breakdown of academic impact, for papers by John F. DiPersio Breakdown of academic impact, for papers by Marina Konopleva
Rankless by CCL
2026